NICE
Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer
January 15, 2020Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma
NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …
NICE rules against the use of Akcea’s Waylivra in the NHS
January 3, 2020Medical Communications Akcea, European Commission, FCS, NHS, NICE
NICE has not recommended Akcea’s drug Waylivra (volanesorsen) to be used for the treatment of Familial Chylomicronaemia Syndrome (FCS) in …
FDA advisory panel back Merck & Co.’s Keytruda treatment for bladder cancer
December 18, 2019Research and Development FDA, Merck, Merck and Co, NHS, NICE, keytruda
An FDA advisory committee voted 9 to 4 in favour of recommending Merk and Co’s Keytruda (pembrolizumab) for treatment in …
NICE reverses previous decision to recommend Vifor Pharma’s Veltassa for NHS treatment of hyperkalaemia
December 16, 2019Sales and Marketing NHS, NICE, Veltassa, Vifor pharma
It has emerged that NICE has awarded its recommendation to Vifor Pharma’s Veltassa (patiromer) for treating hyperkalaemia, a condition classified …
Shionogi’s Mulpleo recommended for NHS use across England, Wales and Scotland for chronic liver disease
December 12, 2019Sales and Marketing England, Mulpleo, NICE, Scotland, Scottish Medicines Consortium, Shionogi, Wales
Both the regulators governing NHS use of medicines in England, Wales and Scotland – the National Institute for Health and …
NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases
December 2, 2019Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma
NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …
Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund
November 28, 2019Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma
Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …
NICE greenlights Consilient Health’s Elmiron for bladder pain syndrome
November 14, 2019Sales and Marketing NICE, consilient health, elmiron, pharma
NICE has chosen to recommend Consilient Health’s Elmiron (pentosan polysulfate sodium) for the treatment of bladder pain syndrome (BPS), it …
Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer
October 11, 2019Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma
NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …
NICE recommends pentosan polysulfate sodium for NHS treatment of bladder pain syndrome
October 10, 2019Sales and Marketing NHS, NICE, bladder pain syndrome, pentosan polysulfate sodium
NICE has chosen to recommend pentosan polysulfate sodium, it has emerged, for use on the NHS in the treatment of …
NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer
October 3, 2019Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq
NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …
NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland
September 26, 2019Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma
NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …
NICE recommends Takeda’s Takhzyro for NHS use to prevent hereditary angioedema attacks
September 18, 2019Research and Development, Sales and Marketing NHS, NICE, Takeda, Takhzyro, pharma
UK drug watchdog NICE has announced its final draft guidance recommending Takeda’s subcutaneous injection Takhzyro (Lanadelumab) for use on the …
NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy
September 4, 2019Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma
NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …
NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy
August 27, 2019Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma
UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …
Latest content
FibroFind appoints Lee Borthwick as CEO
